Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models
Authors:
Open Access
- 15 December 2022
- journal article
- review article
- Published by Elsevier in European Urology Open Science
- Vol. 47, 12-19
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- An Integrated Metabolic Atlas of Clear Cell Renal Cell CarcinomaCancer Cell, 2016
- Renal cell cancer histological subtype distribution differs by race and sexBJU International, 2015
- Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)OncoImmunology, 2015
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic SettingClinical Cancer Research, 2015
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of AngiogenesisCancer Cell, 2013
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell CarcinomaJournal of Urology, 2010
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007